Scholarlink

Background <p>A structured-light robotic system enables noninvasive surface-based facial registration for patient-to-image alignment; however, it has not been widely adopted for basal ganglia hematoma treatment. This study evaluates its safety, accuracy, and efficiency in patients with basal ganglia hematomas.</p> Methods <p>Retrospective consecutive patients with spontaneous basal ganglia hematomas (10–30 mL) admitted from January 2022 to January 2024 were grouped as surgical or non-surgical. Outcomes were analyzed, focusing on registration accuracy and surgical efficiency.</p> Results <p>Baseline preoperative hematoma volume, GCS, NIHSS, and coagulation disorders were comparable between groups (<i>p</i> &gt; 0.05). Mean registration time was 120 ± 56&#xa0;s and surgery time 102.22 ± 6.33&#xa0;min; hematoma clearance was 72% initially and 93% at 7 days. Entry-point discrepancy was 2.2 ± 0.7&#xa0;mm; catheter tip alignment in the upper/middle/lower hematoma segments was 4%/80%/16%, with a maximum 5.7-mm deviation from the midline axis. The surgery group showed faster recovery with higher 24&#xa0;h-GCS (<i>p</i> &lt; 0.001) and better NIHSS/ADL/mRS than non-surgery (<i>p</i> &lt; 0.001 at all time points; <i>p</i> = 0.003 and <i>p</i> = 0.026 at 30 and 90 days; <i>p</i> = 0.041). At 90 days, facial palsy, sensory loss, and ulcers were similar (<i>p</i> &gt; 0.05), whereas pneumonia (<i>p</i> = 0.034) and UTIs (<i>p</i> = 0.002) were lower in the surgery group. No mortality, bleeding, or reoperations occurred.</p> Conclusions <p>Surface registration using the 3D structured light technique is a fast and precise alternative treatment for selected patients with spontaneous medium-volume basal ganglia hematomas, which can improve clinical efficiency while maintaining sufficient accuracy and safety to meet clinical requirements.</p> Trial registration <p>retrospectively registered with approval by the Ethics Committee of Shanghai Fourth people’s hospital, Tongji University School of Medicine (No. 2022327-001).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Innovative 3D structured light technology for robotic-assisted surgery in selected spontaneous medium-volume basal ganglia hematomas: enhancing precision, surgical nuance, and clinical outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月12日

查看全文
  • FuMing Yang,
  • ChengHao Jiang,
  • Wei Wang,
  • ChangYi Zhao,
  • XinRong Chen,
  • Huan Liao,
  • HaiTao Zhang,
  • GuangTing Qiu,
  • JiaoTian Xu,
  • LaiXing Wang,
  • GuoSheng Han,
  • ZhiWen Zhang

摘要

Background

A structured-light robotic system enables noninvasive surface-based facial registration for patient-to-image alignment; however, it has not been widely adopted for basal ganglia hematoma treatment. This study evaluates its safety, accuracy, and efficiency in patients with basal ganglia hematomas.

Methods

Retrospective consecutive patients with spontaneous basal ganglia hematomas (10–30 mL) admitted from January 2022 to January 2024 were grouped as surgical or non-surgical. Outcomes were analyzed, focusing on registration accuracy and surgical efficiency.

Results

Baseline preoperative hematoma volume, GCS, NIHSS, and coagulation disorders were comparable between groups (p > 0.05). Mean registration time was 120 ± 56 s and surgery time 102.22 ± 6.33 min; hematoma clearance was 72% initially and 93% at 7 days. Entry-point discrepancy was 2.2 ± 0.7 mm; catheter tip alignment in the upper/middle/lower hematoma segments was 4%/80%/16%, with a maximum 5.7-mm deviation from the midline axis. The surgery group showed faster recovery with higher 24 h-GCS (p < 0.001) and better NIHSS/ADL/mRS than non-surgery (p < 0.001 at all time points; p = 0.003 and p = 0.026 at 30 and 90 days; p = 0.041). At 90 days, facial palsy, sensory loss, and ulcers were similar (p > 0.05), whereas pneumonia (p = 0.034) and UTIs (p = 0.002) were lower in the surgery group. No mortality, bleeding, or reoperations occurred.

Conclusions

Surface registration using the 3D structured light technique is a fast and precise alternative treatment for selected patients with spontaneous medium-volume basal ganglia hematomas, which can improve clinical efficiency while maintaining sufficient accuracy and safety to meet clinical requirements.

Trial registration

retrospectively registered with approval by the Ethics Committee of Shanghai Fourth people’s hospital, Tongji University School of Medicine (No. 2022327-001).